|
children |
33 |
|
covid-19 |
31 |
|
adolescents |
18 |
|
coronavac |
18 |
|
vaccine |
17 |
|
sars-cov-2 |
16 |
|
allergy |
13 |
|
bnt162b2 |
12 |
|
chinese |
12 |
|
convalescence |
12 |
|
sars-cov-2 rbd igg |
12 |
|
t cell response |
12 |
|
hypersensitivity |
11 |
|
asparaginase |
10 |
|
human leukocyte antigens |
10 |
|
epidemiology |
9 |
|
omicron |
9 |
|
adolescent |
8 |
|
anaphylaxis |
8 |
|
antimicrobial resistance |
8 |
|
bacteria |
8 |
|
drug |
8 |
|
infants |
8 |
|
meningitis |
8 |
|
neonates |
8 |
|
post-covid-19 condition |
8 |
|
quality of life |
8 |
|
symptom burden |
8 |
|
hong kong |
7 |
|
immunological profiles |
7 |
|
saliva |
7 |
|
viral load |
7 |
|
challenge |
6 |
|
coronavirus disease 2019 |
6 |
|
immunity |
6 |
|
immunogenicity |
6 |
|
inborn errors of immunity |
6 |
|
intradermal |
6 |
|
neuromuscular diseases |
6 |
|
paediatrics |
6 |
|
candida |
5 |
|
coronavirus |
5 |
|
hospital |
5 |
|
infection control |
5 |
|
leukemia |
5 |
|
nucleic acid amplification |
5 |
|
policy |
5 |
|
polymerase chain reaction |
5 |
|
renal abscess |
5 |
|
allergy centre |
4 |
|
allergy services |
4 |
|
asia pacific |
4 |
|
asthma |
4 |
|
chronic kidney disease |
4 |
|
dress |
4 |
|
drug reaction with eosinophilia and systemic symptoms |
4 |
|
drug-induced hypersensitivity syndrome |
4 |
|
hospitalisation |
4 |
|
hospitalization |
4 |
|
isolation |
4 |
|
paediatric |
4 |
|
pediatric intensive care units |
4 |
|
prevention |
4 |
|
public health |
4 |
|
status asthmaticus |
4 |
|
stool |
4 |
|
training |
4 |
|
component resolved diagnostics |
3 |
|
component-resolved diagnosis |
3 |
|
desensitization |
3 |
|
fish allergenicity ladder |
3 |
|
fish allergy |
3 |
|
parvalbumin |
3 |
|
peanut allergy |
3 |
|
skin prick test |
3 |
|
allergen discovery |
2 |
|
bupivacaine |
2 |
|
chloroprocaine |
2 |
|
clinical feature |
2 |
|
consumption |
2 |
|
crustaceans |
2 |
|
delayed-type hypersensitivity |
2 |
|
diagnosis |
2 |
|
diagnostic accuracy |
2 |
|
exposure variable |
2 |
|
fish |
2 |
|
generalized reaction |
2 |
|
health policy |
2 |
|
health-related quality of life |
2 |
|
ige |
2 |
|
immunocap sige |
2 |
|
lidocaine |
2 |
|
lignocaine |
2 |
|
local anaesthetic |
2 |
|
measles |
2 |
|
mollusks |
2 |
|
motor |
2 |
|
neuromuscular disorder |
2 |
|
reactivity |
2 |
|
respiratory |
2 |
|
rna-seq |
2 |
|
sensitization |
2 |
|
shellfish |
2 |
|
t-cell mediated |
2 |
|
telerehabilitation |
2 |
|
tolerance |
2 |
|
vaccines |
2 |
|
young children |
2 |
|
β-parvalbumin |
2 |
|
aldolase |
1 |
|
allergic reaction |
1 |
|
allergies |
1 |
|
autoimmunity |
1 |
|
baff |
1 |
|
bcr editing |
1 |
|
cd21low b cells |
1 |
|
celiac |
1 |
|
challenge severity score |
1 |
|
child |
1 |
|
clarkson’s disease |
1 |
|
clinical assessment tool |
1 |
|
collagen |
1 |
|
elimination |
1 |
|
encephalitis |
1 |
|
enolase |
1 |
|
epoetin alfa |
1 |
|
food |
1 |
|
food allergy |
1 |
|
gata2 |
1 |
|
human adenovirus pneumonia |
1 |
|
hypereosinophilia |
1 |
|
ige-mediated |
1 |
|
immunoglobulin |
1 |
|
immunologic |
1 |
|
interferon |
1 |
|
lupus anticoagulant |
1 |
|
myocardial oedema |
1 |
|
non–ige-mediated |
1 |
|
oral food challenge |
1 |
|
pd-1 |
1 |
|
pediatric |
1 |
|
shock |
1 |
|
skin-prick testing |
1 |
|
systemic capillary leak syndrome |
1 |
|
thrombosis |
1 |
|
vasculitis |
1 |
|
west nile virus |
1 |
